It is known that FGFR3 alterations lead to oncogenic signaling through the MAPK and PI3K pathways and that these alterations are particularly sensitive to FGFR inhibitors, leading to the approval of erdafitinib for patients with advanced bladder cancer [38]. The gene discussed is PIK3CA; the disease is urinary bladder carcinoma.